Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorb...
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in p...
The strategic stockpile has been established to enable rapid deployment to EU member states and other countries participating in the EU Civil Protection Me...
Gavi, the Vaccine Alliance, and the Eleanor Crook Foundation (ECF) announced at the Global Vaccine Impact Conference a US$2 million joint investment in the...
Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approved Across all clinical ...
Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform techn...
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were repor...
87% of respondents deemed mRNA a key modality for the future More than 60% of vaccine makers surveyed plan revamp or new facilities for mRNA manufacturi...
SKYCovion is the world’s first-ever vaccine developed using the RoseTTAFold, a software tool that uses deep learning. SK bioscience has appl...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that Nuvaxovid&tra...
After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581...
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met prima...
On March 31, 2023, the government of the Hong Kong Special Administrative Region announced that, from April 20, high-risk groups will be able to receive fr...
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients...
© 2024 Biopharma Boardroom. All Rights Reserved.
